Review top news and interview highlights from the week ending May 3, 2024.
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
A phase 1 trial evaluating INB-200 has shown a PFS benefit in treated participants.
The director of the Mount Sinai Fuster Heart Hospital discussed trends in research and challenges with adopting new therapies.
Based off these data, the phase 2 Regenerate PD trial of AB-1005 will begin enrolling later this year.
The medical director of the Center for Inherited Blood Disorders discussed barriers to the widespread adoption of val-rox by the hemophilia A community.
In anticipation of Bladder Cancer Awareness Month, CGTLive® has decided to take a closer look at this noninterventional real-world study.